Latest news with #Zava
Yahoo
6 days ago
- Business
- Yahoo
Hims & Hers stock price jumps: Telehealth company acquires Zava, picking up over a million Europe customers
American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half of 2025. Following the announcement, Hims' stock price (HIMS) jumped 5.8% in premarket trading. (As of midday Tuesday, the stock was trading up just under one point.) The household auto fleet is a money pit Where are the wildfires in Canada? Maps pinpoint the location of fires and air-quality threats from smoke This company asked most corporate employees to relocate to Chicago. The majority declined The move will rapidly expand Hims & Hers' reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, Ireland, and the U.K., Zava has an active user base of 1.3 million. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers, in a press release. 'By leveraging Zava's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' Expanding to Europe is additionally beneficial because the E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S. This means that personalized telehealth services like Hims & Hers could become more widely accessible there. 'The medications are priced more competitively than in the U.S. so more people can actually afford it and we are seeing a huge demand,' said Zava CEO David Meinertz in an interview with CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.' Hims & Hers' most recent earnings report in May revealed a revenue of $586 million for the quarter, an increase of 111% over the first quarter of last year, as the platform continues to expand. The company's current market cap is $12.5 billion as of Tuesday. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Hims & Hers and Zava, Credo earnings, Kenvue: Trending Tickers
Hims & Hers Health (HIMS) announced it will be acquiring European telehealth platform Zava in an all-cash deal. The stock is falling ahead of Tuesday's market close. Credo Technology (CRDO) shares surge after beating fiscal fourth quarter earnings and revenue estimates. Kenvue (KVUE) shares move to the downside after CEO Tebow Mongeau pointed to certain seasonal challenges this summer at a conference. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. It's time for today's trending tickers. We're watching Hims and Hers Health, Credo Technology, both on the up and up today, as well as Kenvue, which is going in the upper other direction. Starting off with Hims, it's having a rocky day today despite announcements that the company would be acquiring Zava, a European health platform. Him's stock hit some gains when trading opened, but then we saw it turning lower as the morning progressed, so the stock right now down by more than 3%. Most of the analysts have been pretty positive on this one. I did see an interesting note from Allen Letz over at Bank of America, which has an underperform on the stock, and they said, you know, mixed reaction to this. They said this is positive here, but on the negative side, they say if you look at other US healthcare tech companies that have moved into Europe, it hasn't worked out so well. Yeah, I see analysts at uh quoting saying, "On paper, the tie-up makes sense," because they're talking about how Zava offers the same products and services that Hims currently does, also some uh some areas that are on its growth roadmap that call for example, hormone replacement therapy, but they they do see some execution and integration risks. They do call the stock, by the way, they've been on a move already. Something like 100% this year. Yeah, it's been on fire. On fire. All right, Credo Technology. Let's check out that one as well. It's going in the opposite today after the company reported a 400% increase in earnings and 180% increase in sales on a year-to-year basis, leading to huge stock market gains for Credo. So revenue for the fourth quarter, I did see that beat estimates. Revenue was 170 million. It looks like consensus was close to around 160. I see Barclays is saying this is the company's second material beat and raise. Uh this one features, they noted, three large customers versus Amazon alone. Says it's a rare combination of small scale with big tech. Barclays is a buy. By the way, so is buy, so is every single analyst on the street. All 13 buys. Wow! Yeah. A lot of excitement around this company. So networking company, the CEO on the conference call saying, um I think all of the hyperscalers have the potential to be a 10% customer long term. Now, right now, according to Needham estimates, Microsoft accounts for about 12%, XAI accounts for about 11%, um Amazon, it's very reliant on Amazon, 61% of its business last quarter. So I guess if they get less reliant on one client and sort of ever all of these huge hyperscalers are each spending at least 10% with them, I guess analysts think that's a pretty good place to be. And plenty do. It is one of the places to be. Yeah. Seems that way. And let's look at Kenvue. Those shares are seeing some losses after the company CEO, Thibaut Mongon expressed seasonal demand is behind last year's for the company. It's even behind the company's own expectations. He made some comments at a um at a conference today. He said, "It's not a great year so far for allergy and the sun category is more or less the same." By the way, Kenvue, it's not known under its brand name, but it is, if you remember, it spun off in 2023 from Johnson & Johnson. So it has like the consumer-facing brands that had been under J&J. Yeah, consumer products company. Yeah. So this is, they make this presentation, um and the CEO apparently, so he warns about the seasonal demand, as you said, he's uh talked about being behind last year, its own expectations. I mean, not surprisingly, investors reacting. He says, "Not a great year so far for allergy." Uh the sun category more or less the same. On the consumer, making some comments there that were interesting. You're always looking for, you know, what executives are saying and any kind of line of sight you can have into the consumer. Uh this CEO saying, "We definitely see the consumer continuing to be under pressure, regardless of the geography, for slightly different reasons." Interesting. I mean, all of that said, the stock is up about 4% this year. It's up about 15% over the past year. Um most analysts have holds on this thing. There are 15 holds and four buys. As I mentioned, it spun off from J&J back in August of 2023. Kenvue shares are down about round 6% since then. It's interesting. Johnson & Johnson shares are about down about the same amount. So it's not as though the spin-off, you know, caused either one of them to outperform the other.
Yahoo
7 days ago
- Business
- Yahoo
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition grows Hims & Hers' presence in the U.K. and gives the company a foothold in Germany, France, and Ireland, marking the company's biggest international move to date. The terms of the deal weren't disclosed, but the translation is an all-cash one expected to close later this year. Hims & Hers stock was up over 17% Tuesday morning — and is up an astounding 165% year to date. The deal adds more than 1.3 million active users to the company's existing 2.4 million subscriber base and positions Hims & Hers to roll out its digital healthcare model in some of Europe's largest healthcare markets. Weight-loss drugs will likely be a central part of that expansion. Andrew Dudum, Hims & Hers' CEO, told The Financial Times that there's a 'huge opportunity' in obesity, noting that Zava already offers branded weight-loss treatments and has seen growing demand. Hims & Hers is perhaps best known in the U.S. for its direct-to-consumer offerings across categories such as hair loss, sexual health, and anxiety — but its compounded GLP-1 medications have become one of its fastest-growing offerings. The company, which recently struck a deal to offer Novo Nordisk's Wegovy, has been threading a regulatory needle: offering custom formulations to a 'meaningfully smaller group of patients,' as CEO Andrew Dudum put it to The Financial Times. With the Zava deal, similar offerings could be on the horizon for Europe. In the U.K., compounded medications can legally be dispensed under certain conditions, providing an opening for Hims & Hers' approach. Lower pharmaceutical prices and public health system constraints could accelerate adoption. And with U.S. compounding regulations tightening and the branded supply stabilizing, international expansion could create a path for further growth. This isn't Hims & Hers' first international foray — the company acquired London-based Honest Health in 2021 — but the Zava deal adds an established European presence and could position Hims & Hers to build a branded footprint in key European markets while leveraging Zava's infrastructure. 'Early traction in the U.K. gives us confidence that we can scale our platform globally,' Dudum said on his company's recent earnings call. Zava CEO and co-founder David Meinertz will remain on board as general manager of the international business, and the Zava brand will reportedly stay live for a few quarters before rebranding as Hims & Hers. Meinertz said the deal could help ease pressure on Europe's strained healthcare systems. 'The medications are priced more competitively than in the U.S., so more people can actually afford it, and we are seeing a huge demand,' Meinertz told CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.' Hims & Hers is betting on that growing pressure on national health systems. 'Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve,' Dudum said in the company's press release. 'The demand for simpler, more personalized healthcare is universal.' For the latest news, Facebook, Twitter and Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
7 days ago
- Business
- Time of India
Hims to acquire UK-based startup Zava as it expands international presence
New York: Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients. The move comes as Hims is adjusting to a regulatory ban in the United States on manufacturing mass copies of Novo Nordisk's popular weight-loss drug Wegovy, that took effect on May 22. Hims began offering copies of Wegovy in 2024, and saw a boost in its revenues, when the branded version of the highly in-demand drug was in shortage. Shares of the telehealth firm have dropped nearly 9% in the last two weeks. It recently entered into an agreement with Novo to help patients access brand-name Wegovy, and plans to enter the market for low testosterone and menopause treatments in pursuit of new growth opportunities. Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its second-quarter results expected in August. It plans to fund the acquisition through cash on its balance sheet at closing. The deal is expected to close in the second half of this year. Backed by equity firm HPE Growth, Zava provides medical consultations and delivery of prescription medicines - including weight loss drugs Mounjaro and Wegovy - to its more than 1 million customers across United Kingdom, Germany, France and Ireland. Hims said it plans to introduce personalized skin care, weight loss and other offerings for patients in these markets and will introduce an option for patients to interact with their healthcare providers in local languages. Last week, Hims also said it will cut about 4% of its workforce but still plans to hire for roles related to its long-term growth strategy.
Fast Company
03-06-2025
- Business
- Fast Company
Hims & Hers stock price jumps: Telehealth company acquires Zava, picking up over a million Europe customers
American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half of 2025. Following the announcement, Hims' stock price (HIMS) jumped 5.8% in premarket trading. (As of midday Tuesday, the stock was trading up just under one point.) The move will rapidly expand Hims & Hers' reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, Ireland, and the U.K., Zava has an active user base of 1.3 million. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers, in a press release. 'By leveraging Zava's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' Expanding to Europe is additionally beneficial because the E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S. This means that personalized telehealth services like Hims & Hers could become more widely accessible there. 'The medications are priced more competitively than in the U.S. so more people can actually afford it and we are seeing a huge demand,' said Zava CEO David Meinertz in an interview with CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.'
